ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® [Yahoo! Finance]
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth [Yahoo! Finance]
ImmuCell (NASDAQ:ICCC) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
ImmuCell signals operational excellence and targets $30M annual production capacity amid management transition [Seeking Alpha]